Is hydroxyzine appropriate and safe for use as a short‑term sleep aid in adolescents, and what dosing and monitoring recommendations apply?

Hydroxyzine for Sleep in Teens: Not Recommended as First-Line

Hydroxyzine should not be used as a first-line sleep aid in adolescents due to significant safety concerns, lack of efficacy evidence for insomnia, and availability of better alternatives. While it may be considered for very short-term anxiolysis in specific clinical contexts, its use for sleep is not supported by guidelines and carries substantial risks in this population.

Key Safety Concerns in Adolescents

The FDA label explicitly warns about multiple serious risks that are particularly concerning in teenagers 1:

• QT prolongation and Torsade de Pointes: Cases reported post-marketing, especially problematic given teens' potential concomitant use of other QT-prolonging medications (SSRIs, antipsychotics)
• Performance impairment without subjective awareness: Teens may not recognize they are impaired while driving or in school 2
• Fatal accident risk: Drivers taking first-generation antihistamines like hydroxyzine are 1.5 times more likely to be responsible for fatal automobile accidents 2
• Impaired learning and school performance: Documented in children and adolescents 2
• Paradoxical CNS stimulation: Particularly occurs in children and adolescents 2
• Anticholinergic effects: Dry mouth, constipation, urinary retention 2

Guideline Recommendations Against Use

The 2017 American Academy of Sleep Medicine guideline for chronic insomnia explicitly states there is "sparse or little evidence" to support first-generation H1 antagonists (including hydroxyzine) for insomnia, with only "preliminary but conflicting evidence" for short-term use 3. The guideline notes "lack of demonstrated efficacy as well as safety concerns" for over-the-counter antihistamine sleeping aids 3.

Multiple rhinitis guidelines emphasize that even when dosed only at bedtime, first-generation antihistamines cause significant daytime drowsiness, decreased alertness, and performance impairment due to prolonged plasma half-lives 2. This is particularly problematic for adolescents who need to function in school and may be driving.

Limited and Conflicting Evidence

The evidence base for hydroxyzine in pediatric sleep is extremely weak:

• No controlled trials in healthy adolescents with insomnia: The 2023 systematic review found only adult studies with mixed efficacy 4
• Atopic dermatitis studies show tolerance develops: Children develop tolerance to sedating properties while anticholinergic side effects persist 5
• Antihistamines don't improve pruritus in trials: Suggesting any sleep benefit is purely from sedation, not addressing underlying causes 5
• Recent prescribing data shows increasing off-label use: A 2024 US study found hydroxyzine among the most commonly prescribed sleep medications in youth, but this reflects practice patterns, not evidence 6. A 2025 French study documented a 38% increase in hydroxyzine prescriptions post-pandemic, raising concerns about inappropriate use 7

What Should Be Used Instead

For adolescent insomnia, the evidence-based approach is:

1. Cognitive-behavioral therapy for insomnia (CBT-I) as first-line treatment 3: This is the standard of care with strong evidence in adults and emerging evidence in adolescents

2. Sleep hygiene and behavioral interventions: Consistent bedtime routines, limiting screen time, addressing circadian factors 5, 8

3. For delayed sleep-wake phase disorder (common in teens):

   • Melatonin 0.15 mg/kg (or 3-5 mg) taken 1.5-2 hours before desired bedtime has moderate-quality evidence in adolescents 9
   • Dosing: 3 mg if <40 kg; 5 mg if >40 kg 9
   • This addresses the circadian component rather than just sedating

4. Address underlying psychiatric comorbidities: 75% of youth with insomnia have comorbid anxiety, depression, or ADHD 6 - treating these is essential

When Hydroxyzine Might Be Considered (Rarely)

The only contexts where hydroxyzine has any role in adolescents:

• Short-term anxiolysis (not specifically for sleep): The 2023 EANM guideline mentions hydroxyzine as approved for anxiolytic use in children for medical procedures 10, but this is for anxiety management, not insomnia treatment
• Very short-term use (days, not weeks) when other options have failed and anxiety is the primary driver
• Never as monotherapy for insomnia without addressing underlying causes

Dosing and Monitoring If Used (Against Recommendation)

If hydroxyzine is used despite these concerns (which I do not recommend):

• Dose: The FDA label does not provide pediatric dosing for insomnia. Studies in atopic dermatitis used 0.7 mg/kg TID 11, but this is not applicable to sleep
• Monitoring required 1:
  • Baseline and follow-up ECG if any cardiac risk factors
  • Assess for daytime sedation, school performance
  • Evaluate for paradoxical stimulation
  • Monitor for anticholinergic effects
  • Discontinue immediately if skin reactions occur (AGEP risk)

Critical Pitfalls to Avoid

• Don't use hydroxyzine just because it's "sedating": Sedation ≠ healthy sleep architecture
• Don't assume teens will report sedation: Performance impairment exists without subjective awareness 2
• Don't combine with other CNS depressants: Including alcohol, which teens may experiment with 2, 1
• Don't use long-term: Tolerance develops while side effects persist 5
• Don't ignore the 1.5x fatal accident risk: This is a real mortality concern in driving-age adolescents 2

In summary: Hydroxyzine lacks efficacy evidence for adolescent insomnia, carries significant safety risks including impaired driving and school performance, and contradicts guideline recommendations. Melatonin for circadian disorders and CBT-I for insomnia are evidence-based alternatives that should be used instead.